Discovering New Precision Medicines

Our Science

Building on an exceptional track record of innovation, this team brings a wealth of cross-functional expertise to successful rational drug design. We focus on pioneering best-in-class therapeutics to improve upon existing drugs with clear liabilities, as well as to create new breakthroughs for diseases where others have been unable to find solutions.

Established and emerging science will guide our plans, with an emphasis on rare disease patient populations with well-characterized biology, allowing us to move rapidly and create meaningful impact for patients.

Our Bezuclastinib Approach
Our FGFR Approach
Fibroblast growth factor receptors (FGFRs) are a family of transmembrane receptors consisting of isoforms FGFR1-FGFR4
Binding of a ligand to the inactive FGFR monomer leads to receptor dimerization, phosphorylation, and downstream signaling
Receptor mutations, amplifications, and fusions can result in activation of FGFRs and are recognized as well-established oncogenic drivers in multiple indications
Inhibition of FGFR3 mutations in urothelial cancer and FGFR2 fusions in cholangiocarcinoma has led to improved clinical outcomes in defined patient populations

Inhibition Ligand Independent Signaling in FGFR 2/3 Altered Tumors is a Clinically Proven Approach

Posters and Publications
Scroll to Top
Cole Pinnow

Chief Commercial Officer

Cole is an accomplished executive with extensive commercial development, new product launch, P&L, and strategic leadership experience over a 20 plus year career in the pharmaceutical industry, with a specific focus on oncology. Before joining Cogent as Chief Commercial Officer, he served at Pfizer as the Global Franchise Lead for its Genitourinary, Lung and Breast Oncology Businesses. In this role, he oversaw the global launch and lifecycle strategy for Xtandi® + Talzenna® in mCRPC. Before that, he was President of Pfizer Canada where he was accountable for the company’s operations within the country, including sales, marketing, access and government relations. He was also VP of a US commercial business unit which had tremendous growth under his leadership. Prior to working at Pfizer, Cole held management positions at both Hospira, Inc., a global pharmaceutical and medical device company, in global pharmaceuticals, global marketing and commercial development. He holds an MBA from the University of Chicago Booth School of Business, a Master of Science degree in Microbiology from Iowa State University, and a Bachelor’s Degree in Biology from St. Olaf College. In his spare time, Cole enjoys swimming, hiking and skiing.